{"protocolSection": {"identificationModule": {"nctId": "NCT00216476", "orgStudyIdInfo": {"id": "CR002269"}, "organization": {"fullName": "Janssen-Cilag International NV", "class": "INDUSTRY"}, "briefTitle": "A Study of Relapse Prevention and the Effectiveness of Long-acting Injectable Risperidone and Quetiapine Tablets in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder", "officialTitle": "CONSTATRE: Risperdal Consta Trial Of Relapse Prevention And Effectiveness"}, "statusModule": {"statusVerifiedDate": "2014-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2004-10"}, "primaryCompletionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "studyFirstSubmitDate": "2005-09-13", "studyFirstSubmitQcDate": "2005-09-14", "studyFirstPostDateStruct": {"date": "2005-09-22", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-07-08", "resultsFirstSubmitQcDate": "2010-07-08", "resultsFirstPostDateStruct": {"date": "2010-08-10", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2014-03-25", "lastUpdatePostDateStruct": {"date": "2014-04-16", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Janssen-Cilag International NV", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to investigate whether a long-acting injectable formulation of risperidone provides better effectiveness over 2 years, as measured by the time to relapse, compared with quetiapine tablets in a routine psychiatric care setting. Aripiprazole will be investigated in a descriptive manner.", "detailedDescription": "Although many schizophrenia patients currently take oral antipsychotic medications, it is estimated that up to 75% of them have difficulty adhering to the daily oral regimen. Long-acting injectable formulations may eliminate the need for daily medication and enhance patient compliance with the treatment regimen. This is an open-label (all people involved know the identity of the intervention), randomized (study drug assigned by chance) study of a formulation of risperidone (coated microspheres) injected into the muscle at 2 week intervals over 104 weeks in stable patients with schizophrenia or schizoaffective disorder, who are being treated with oral risperidone, olanzapine, or other conventional antipsychotic agents. A comparator group will receive tablets of quetiapine to be taken 2 or 3 times daily, depending on the optimal dosage. In countries where aripiprazole is available, aripiprazole was also included in a descriptive manner. Reasons for switching symptomatically stable patients from their current antipsychotic treatment include insufficient effectiveness of the medication on symptoms, adverse events, or a patient's request. The principal measure of effectiveness of the drug is the time to relapse. Assessments of effectiveness also include: Positive and Negative Syndrome Scale (PANSS), which measures the symptoms of schizophrenia; overall severity of illness measured by the Clinical Global Impression subscale (CGI-S); patient's condition measured by the Clinical Global Impression condition subscale (CGI-C); quality of life assessed by the SF-12 survey. Safety evaluations include incidence of adverse events, Extrapyramidal Symptoms Rating Scale (ESRS), clinical laboratory tests (biochemistry, haematology, and urinalysis), and vital signs (pulse, blood pressure). The study hypothesis is that treatment with long-acting risperidone injected intramuscularly every 2 weeks provides better effectiveness than quetiapine, as measured by time to relapse, in patients with schizophrenia or schizoaffective disorder. Risperidone injections 25mg biweekly for 104 weeks, increasing or decreasing (increments of 12.5mg) at investigator's discretion. Risperidone tablets (2mg daily for 2 days) for patients starting on risperidone. Quetiapine and Aripiprazole used according to package insert."}, "conditionsModule": {"conditions": ["Schizophrenia", "Psychotic Disorders"], "keywords": ["Schizophrenia, relapse prevention", "Antipsychotic agents", "Long-acting risperidone", "Quetiapine", "Aripiprazole"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 753, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "001", "type": "EXPERIMENTAL", "description": "Risperidone Long Acting Injectable (LAI) 25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.", "interventionNames": ["Drug: Risperidone Long Acting Injectable (LAI)"]}, {"label": "002", "type": "ACTIVE_COMPARATOR", "description": "Quetiapine Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.", "interventionNames": ["Drug: Quetiapine"]}, {"label": "003", "type": "OTHER", "description": "Aripiprazole 10-30 mg oral once daily for 104 weeks", "interventionNames": ["Drug: Aripiprazole"]}], "interventions": [{"type": "DRUG", "name": "Aripiprazole", "description": "10-30 mg oral once daily for 104 weeks", "armGroupLabels": ["003"]}, {"type": "DRUG", "name": "Risperidone Long Acting Injectable (LAI)", "description": "25 mg injection every 2 weeks until week 104. Dosage may be increased or decreased in steps of 12.5 mg. Additional oral risperidone can be administered as required until a dose increase becomes effective.", "armGroupLabels": ["001"]}, {"type": "DRUG", "name": "Quetiapine", "description": "Oral tablets are titrated from 50 mg daily to 300-400 mg daily in first 4 days. Subsequently treatment is maintained for 104 weeks and dosage can be adjusted with increments or decrements of 25 to 50 mg.", "armGroupLabels": ["002"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Mean Relapse Free Period(Risperidone LAI Versus Quetiapine)", "description": "Relapse was defined as meeting any of the predefined criteria (adapted from Csernansky et al., 2002) on 2 consecutive evaluations during treatment, 3 to 5 days apart. The relapse rate in each treatment arm was estimated using the Kaplan-Meier method.", "timeFrame": "Assessed at each visit from the moment the subject was randomized to a treatment arm (baseline visit) until the end of treatment (Week 104 or earlier)"}], "secondaryOutcomes": [{"measure": "Mean Relapse Free Period (Exploratory/Aripiprazole)", "description": "As for risperidone and quetiapine, relapse was defined as meeting any of the predefined criteria (adapted from Csernansky et al., 2002) on 2 consecutive evaluations during treatment, 3 to 5 days apart. Since aripiprazole was new on the market at the time the study was conducted, this aripiprazole analysis was exploratory.", "timeFrame": "Assessed at each visit from the moment the subject was randomized to a treatment arm (baseline visit) until the end of treatment (Week 104 or earlier)"}, {"measure": "Change From Baseline to Endpoint in Total Positive and Negative Syndrome Scale (PANSS) Score", "description": "The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item PANSS scale. The PANSS scale provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, i.e., the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items).\n\nEach item of the scale is to be scored on a scale of 1 (absent) to 7 (extreme).", "timeFrame": "Assessed at each visit from the moment the subject was randomized to a treatment arm (baseline visit) until the end of treatment (Week 104 or earlier)"}, {"measure": "Change From Baseline to Endpoint in Clinical Global Impression Scale (CGI) Score", "description": "The 7-point CGI scale of Severity (CGI-S) was used to assess the severity of a subject's psychotic condition (0= normal, not at all ill, 1= borderline, etc. and 6= among the most extremely ill subjects).", "timeFrame": "Assessed at each visit from the moment the subject was randomized to a treatment arm (baseline visit) until the end of treatment (Month 24 or earlier)"}, {"measure": "Change From Baseline to Endpoint in Short-Form Health Survey 12 (SF-12) Scores", "description": "Quality of life was assessed by means of the 12-item SF-12\u00ae survey. Two parameters, i.e., PCS (physical component summary) and MCS (mental component summary) were calculated. Both components scores range from 0 to 100 with higher scores indicating better QOL.", "timeFrame": "Assessed at the moment the subject was randomized to a treatment arm (baseline visit) and after 1, 3, 6, 12, 18, and 24 months of treatment"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Diagnosis of schizophrenia or schizoaffective disorder according to the Diagnostic and Statistical Manual of Mental Diseases, 4th edition (DSM-IV)\n* Patients currently treated with oral risperidone, olanzapine or a conventional neuroleptic monotherapy at doses not exceeding 6 mg risperdal, 20 mg olanzapine, or a conversion dose of 10 mg haloperidol for oral conventional agents\n* Patients who are stable (judged clinically stable by the investigator and on a stable dose of medication for 4 weeks or longer) but not optimally treated (non-satisfactory treatment regarding symptoms or adverse events)\n\nExclusion Criteria:\n\n* Diagnosis other than schizophrenia or schizoaffective disorder by DSM-IV Axis I criteria\n* Patients being treated with antipsychotic agents other than oral risperidone, olanzapine or conventional oral neuroleptic agents\n* Patients with known hypersensitivity to oral risperidone, quetiapine, aripiprazole, or who are known non-responders to oral risperidone, quetiapine, aripiprazole or to previous treatment with at least 2 antipsychotic agents\n* Patients treated with mood stabilizers or antidepressants who are not on stable dose for at least 3 months before study initiation\n* Pregnant or nursing females, or those lacking adequate contraception", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Janssen-Cilag International NV Clinical Trial", "affiliation": "Janssen-Cilag International NV", "role": "STUDY_DIRECTOR"}], "locations": [{"city": "Hall In Tirol", "country": "Austria", "geoPoint": {"lat": 47.28333, "lon": 11.51667}}, {"city": "Linz", "country": "Austria", "geoPoint": {"lat": 48.30639, "lon": 14.28611}}, {"city": "Neunkirchen", "country": "Austria", "geoPoint": {"lat": 47.72096, "lon": 16.08107}}, {"city": "Pleven", "country": "Bulgaria", "geoPoint": {"lat": 43.41667, "lon": 24.61667}}, {"city": "Sofia Sofia", "country": "Bulgaria"}, {"city": "Sofia", "country": "Bulgaria", "geoPoint": {"lat": 42.69751, "lon": 23.32415}}, {"city": "Osijek", "country": "Croatia", "geoPoint": {"lat": 45.55111, "lon": 18.69389}}, {"city": "Rijeka", "country": "Croatia", "geoPoint": {"lat": 45.32674, "lon": 14.44239}}, {"city": "Split", "country": "Croatia", "geoPoint": {"lat": 43.50891, "lon": 16.43915}}, {"city": "Zagreb", "country": "Croatia", "geoPoint": {"lat": 45.81444, "lon": 15.97798}}, {"city": "Brno", "country": "Czech Republic", "geoPoint": {"lat": 49.19522, "lon": 16.60796}}, {"city": "Lnare", "country": "Czech Republic", "geoPoint": {"lat": 49.4579, "lon": 13.78406}}, {"city": "Opava N/A", "country": "Czech Republic"}, {"city": "Pardubice", "country": "Czech Republic", "geoPoint": {"lat": 50.04075, "lon": 15.77659}}, {"city": "Plzen Czechia", "country": "Czech Republic", "geoPoint": {"lat": 49.74747, "lon": 13.37759}}, {"city": "Praha 2 N/A", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Praha 8", "country": "Czech Republic", "geoPoint": {"lat": 50.08804, "lon": 14.42076}}, {"city": "Uhersky Brod", "country": "Czech Republic", "geoPoint": {"lat": 49.02513, "lon": 17.64715}}, {"city": "Usti Nad Labem N/A", "country": "Czech Republic"}, {"city": "Middelfart N/A", "country": "Denmark"}, {"city": "Vordingborg N/A", "country": "Denmark"}, {"city": "P\u00ffrnu N/A", "country": "Estonia"}, {"city": "Tallinn N/A", "country": "Estonia", "geoPoint": {"lat": 59.43696, "lon": 24.75353}}, {"city": "Tartu N/A", "country": "Estonia"}, {"city": "Bron N/A", "country": "France"}, {"city": "Brumath Cedex", "country": "France", "geoPoint": {"lat": 48.73014, "lon": 7.7121}}, {"city": "Creteil", "country": "France", "geoPoint": {"lat": 48.78333, "lon": 2.46667}}, {"city": "Dieppe N/A", "country": "France"}, {"city": "Henin Beaumont", "country": "France", "geoPoint": {"lat": 50.41359, "lon": 2.96485}}, {"city": "Mont St Martin", "country": "France", "geoPoint": {"lat": 49.54669, "lon": 5.79375}}, {"city": "Poitiers N/A", "country": "France"}, {"city": "Reims", "country": "France", "geoPoint": {"lat": 49.25, "lon": 4.03333}}, {"city": "Roubaix", "country": "France", "geoPoint": {"lat": 50.69421, "lon": 3.17456}}, {"city": "Toulouse N/A", "country": "France"}, {"city": "Augsburg", "country": "Germany", "geoPoint": {"lat": 48.37154, "lon": 10.89851}}, {"city": "Berlin", "country": "Germany", "geoPoint": {"lat": 52.52437, "lon": 13.41053}}, {"city": "Bochum", "country": "Germany", "geoPoint": {"lat": 51.48165, "lon": 7.21648}}, {"city": "Duisburg", "country": "Germany", "geoPoint": {"lat": 51.43247, "lon": 6.76516}}, {"city": "D\u00fcsseldorf", "country": "Germany", "geoPoint": {"lat": 51.22172, "lon": 6.77616}}, {"city": "Karlstadt", "country": "Germany", "geoPoint": {"lat": 49.96034, "lon": 9.77239}}, {"city": "Krefeld", "country": "Germany", "geoPoint": {"lat": 51.33645, "lon": 6.55382}}, {"city": "M\u00fcnchen", "country": "Germany", "geoPoint": {"lat": 48.13743, "lon": 11.57549}}, {"city": "Oranienburg", "country": "Germany", "geoPoint": {"lat": 52.75577, "lon": 13.24197}}, {"city": "Stralsund", "country": "Germany", "geoPoint": {"lat": 54.30911, "lon": 13.0818}}, {"city": "Heraklion -Crete", "country": "Greece"}, {"city": "Thessalonikis", "country": "Greece"}, {"city": "Budapest N/A", "country": "Hungary"}, {"city": "Budapest", "country": "Hungary", "geoPoint": {"lat": 47.49801, "lon": 19.03991}}, {"city": "Gyula", "country": "Hungary", "geoPoint": {"lat": 46.65, "lon": 21.28333}}, {"city": "Gy\u00f5r", "country": "Hungary", "geoPoint": {"lat": 47.68333, "lon": 17.63512}}, {"city": "Kistarcsa", "country": "Hungary", "geoPoint": {"lat": 47.54757, "lon": 19.26247}}, {"city": "Szeged N/A", "country": "Hungary"}, {"city": "Vac N/A", "country": "Hungary"}, {"city": "Cork", "country": "Ireland", "geoPoint": {"lat": 51.89797, "lon": -8.47061}}, {"city": "Dublin N/A", "country": "Ireland", "geoPoint": {"lat": 53.33306, "lon": -6.24889}}, {"city": "Kerry", "country": "Ireland"}, {"city": "Sligo N/A", "country": "Ireland"}, {"city": "Jerusalem", "country": "Israel", "geoPoint": {"lat": 31.76904, "lon": 35.21633}}, {"city": "Ramat-Gan", "country": "Israel", "geoPoint": {"lat": 32.08227, "lon": 34.81065}}, {"city": "Tel Aviv", "country": "Israel", "geoPoint": {"lat": 32.08088, "lon": 34.78057}}, {"city": "Jelgava", "country": "Latvia", "geoPoint": {"lat": 56.65, "lon": 23.71278}}, {"city": "Riga", "country": "Latvia", "geoPoint": {"lat": 56.946, "lon": 24.10589}}, {"city": "Alytus", "country": "Lithuania", "geoPoint": {"lat": 54.39636, "lon": 24.04143}}, {"city": "Kaunas", "country": "Lithuania", "geoPoint": {"lat": 54.90272, "lon": 23.90961}}, {"city": "Klaipeda", "country": "Lithuania", "geoPoint": {"lat": 55.70888, "lon": 21.14311}}, {"city": "Siauliai", "country": "Lithuania", "geoPoint": {"lat": 55.93333, "lon": 23.31667}}, {"city": "Vilnius", "country": "Lithuania", "geoPoint": {"lat": 54.68916, "lon": 25.2798}}, {"city": "Choroszcz", "country": "Poland", "geoPoint": {"lat": 53.14332, "lon": 22.98889}}, {"city": "Gdynia Na", "country": "Poland"}, {"city": "Poznan", "country": "Poland", "geoPoint": {"lat": 52.40692, "lon": 16.92993}}, {"city": "Warszawa", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"city": "Coimbra", "country": "Portugal", "geoPoint": {"lat": 40.20564, "lon": -8.41955}}, {"city": "Porto N/A", "country": "Portugal"}, {"city": "Bucharest", "country": "Romania", "geoPoint": {"lat": 44.43225, "lon": 26.10626}}, {"city": "Bucuresti", "country": "Romania", "geoPoint": {"lat": 44.42802, "lon": 26.09665}}, {"city": "Craiova", "country": "Romania", "geoPoint": {"lat": 44.31667, "lon": 23.8}}, {"city": "Iasi", "country": "Romania", "geoPoint": {"lat": 47.16667, "lon": 27.6}}, {"city": "Al Khobar", "country": "Saudi Arabia"}, {"city": "Kosice", "country": "Slovakia", "geoPoint": {"lat": 48.71395, "lon": 21.25808}}, {"city": "Zvolen", "country": "Slovakia", "geoPoint": {"lat": 48.57442, "lon": 19.15324}}, {"city": "Begunje", "country": "Slovenia"}, {"city": "Ljubljana", "country": "Slovenia", "geoPoint": {"lat": 46.05108, "lon": 14.50513}}, {"city": "Ormoz", "country": "Slovenia", "geoPoint": {"lat": 46.41139, "lon": 16.15444}}, {"city": "Madrid", "country": "Spain", "geoPoint": {"lat": 40.4165, "lon": -3.70256}}, {"city": "Oviedo (Asturias)", "country": "Spain"}, {"city": "Sevilla N/A", "country": "Spain", "geoPoint": {"lat": 37.38283, "lon": -5.97317}}, {"city": "Valencia N/A", "country": "Spain"}, {"city": "G\u00f6teborg", "country": "Sweden", "geoPoint": {"lat": 57.70716, "lon": 11.96679}}, {"city": "Trollh\u00e4ttan", "country": "Sweden", "geoPoint": {"lat": 58.28365, "lon": 12.28864}}, {"city": "Ankara Turkey", "country": "Turkey"}, {"city": "Bakirkoy/Istanbul N/A", "country": "Turkey"}, {"city": "Istanbul", "country": "Turkey", "geoPoint": {"lat": 41.01384, "lon": 28.94966}}, {"city": "Izmir", "country": "Turkey", "geoPoint": {"lat": 38.41273, "lon": 27.13838}}, {"city": "Barnet", "country": "United Kingdom", "geoPoint": {"lat": 51.65, "lon": -0.2}}, {"city": "Barnsley", "country": "United Kingdom", "geoPoint": {"lat": 53.55, "lon": -1.48333}}, {"city": "Hull", "country": "United Kingdom", "geoPoint": {"lat": 53.7446, "lon": -0.33525}}, {"city": "Llantrissant", "country": "United Kingdom"}, {"city": "Swansea", "country": "United Kingdom", "geoPoint": {"lat": 51.62079, "lon": -3.94323}}]}, "referencesModule": {"seeAlsoLinks": [{"label": "CONSTATRE: Risperdal\ufffd Consta\ufffd Trial of Relapse Prevention and Effectiveness RIS-SCH-3001 Study Results Synopsis", "url": "http://filehosting.pharmacm.com/DownloadService.ashx?client=CTR_JNJ_6051&studyid=46&filename=CR002269_CSR.pdf"}]}}, "resultsSection": {"participantFlowModule": {"recruitmentDetails": "Subjects had a diagnosis of schizophrenia or schizoaffective disorder (according to the Diagnostic and Statistical Manual of Mental Disorders - 4th edition \\[DSM-IV\\]) and were treated with oral risperidone, olanzapine, or conventional oral neuroleptic monotherapy at screening. They were to be symptomatically stable but not optimally treated.", "groups": [{"id": "FG000", "title": "Risperidone LAI", "description": "Risperidone Long Acting Injectable (LAI) intramuscular injection, dose of 25, 37.5, or 50 mg every 2 weeks"}, {"id": "FG001", "title": "Quetiapine", "description": "oral Quetiapine, target dose of 300-400 mg twice daily (b.i.d.) or three times daily (t.i.d.)"}, {"id": "FG002", "title": "Aripiprazole", "description": "oral Aripiprazole, recommended maintenance dose of 10-30 mg once daily (q.d.)"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "329"}, {"groupId": "FG001", "numSubjects": "337"}, {"groupId": "FG002", "numSubjects": "45"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "224"}, {"groupId": "FG001", "numSubjects": "230"}, {"groupId": "FG002", "numSubjects": "28"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "105"}, {"groupId": "FG001", "numSubjects": "107"}, {"groupId": "FG002", "numSubjects": "17"}]}], "dropWithdraws": [{"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "59"}, {"groupId": "FG001", "numSubjects": "72"}, {"groupId": "FG002", "numSubjects": "9"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "10"}, {"groupId": "FG001", "numSubjects": "9"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "6"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "3"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Other", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Refuses Injection", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "No Further Need for Treatment", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Non-compliance", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "4"}, {"groupId": "FG002", "numSubjects": "1"}]}, {"type": "Higher dose/Extra Medication Required", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "2"}]}, {"type": "Administrative Reasons", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Protocol Deviation", "reasons": [{"groupId": "FG000", "numSubjects": "5"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "0"}]}, {"type": "Patient Moved", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Risperidone LAI", "description": "intramuscular injection, dose of 25, 37.5, or 50 mg every 2 weeks"}, {"id": "BG001", "title": "Quetiapine", "description": "oral, target dose of 300-400 mg b.i.d. or t.i.d."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "329"}, {"groupId": "BG001", "value": "337"}, {"groupId": "BG002", "value": "666"}]}], "measures": [{"title": "Age, Continuous", "description": "As aripiprazole was not part of the primary analysis but was only added for exploratory purposes, data on this arm are not presented here.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "40.6", "spread": "12.48"}, {"groupId": "BG001", "value": "42.6", "spread": "13.14"}, {"groupId": "BG002", "value": "41.6", "spread": "12.85"}]}]}]}, {"title": "Sex: Female, Male", "description": "As aripiprazole was not part of the primary analysis but was only added for exploratory purposes, data on this arm are not presented here.", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "134"}, {"groupId": "BG001", "value": "146"}, {"groupId": "BG002", "value": "280"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "195"}, {"groupId": "BG001", "value": "191"}, {"groupId": "BG002", "value": "386"}]}]}]}, {"title": "Race/Ethnicity, Customized", "description": "As aripiprazole was not part of the primary analysis but was only added for exploratory purposes, data on this arm are not presented here.", "paramType": "NUMBER", "unitOfMeasure": "participants", "classes": [{"title": "Caucasian", "categories": [{"measurements": [{"groupId": "BG000", "value": "320"}, {"groupId": "BG001", "value": "330"}, {"groupId": "BG002", "value": "650"}]}]}, {"title": "Oriental", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "2"}, {"groupId": "BG002", "value": "3"}]}]}, {"title": "Hispanic", "categories": [{"measurements": [{"groupId": "BG000", "value": "2"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "2"}]}]}, {"title": "Black", "categories": [{"measurements": [{"groupId": "BG000", "value": "1"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}]}]}, {"title": "Arab", "categories": [{"measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "4"}, {"groupId": "BG002", "value": "9"}]}]}, {"title": "Pakistani", "categories": [{"measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "1"}]}]}]}, {"title": "Body Mass Index (BMI)", "description": "As aripiprazole was not part of the primary analysis but was only added for exploratory purposes, data on this arm are not presented here.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg/m2", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "27.6", "spread": "5.23"}, {"groupId": "BG001", "value": "27.0", "spread": "5.32"}, {"groupId": "BG002", "value": "27.3", "spread": "5.28"}]}]}]}, {"title": "Weight", "description": "As aripiprazole was not part of the primary analysis but was only added for exploratory purposes, data on this arm are not presented here.", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "80.4", "spread": "16.93"}, {"groupId": "BG001", "value": "79.0", "spread": "17.75"}, {"groupId": "BG002", "value": "79.7", "spread": "17.35"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Mean Relapse Free Period(Risperidone LAI Versus Quetiapine)", "description": "Relapse was defined as meeting any of the predefined criteria (adapted from Csernansky et al., 2002) on 2 consecutive evaluations during treatment, 3 to 5 days apart. The relapse rate in each treatment arm was estimated using the Kaplan-Meier method.", "populationDescription": "Efficacy analysis set, defined as all subjects who received at least 1 dose of study medication and who had at least 1 efficacy assessment after baseline. This excluded 2 subjects of the risperidone LAI arm and 11 of the quetiapine arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "days", "timeFrame": "Assessed at each visit from the moment the subject was randomized to a treatment arm (baseline visit) until the end of treatment (Week 104 or earlier)", "groups": [{"id": "OG000", "title": "Risperidone LAI", "description": "intramuscular injection, dose of 25, 37.5, or 50 mg every 2 weeks"}, {"id": "OG001", "title": "Quetiapine", "description": "oral, target dose of 300-400 mg b.i.d. or t.i.d."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "327"}, {"groupId": "OG001", "value": "326"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "607", "spread": "11.4"}, {"groupId": "OG001", "value": "533", "spread": "15.6"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Null hypothesis was that there is no difference in treatment effect between risperidone LAI and quetiapine by mean relapse free period; given a estimated relapse rate of 30% for risperidone LAI and 42% for quetiapine, with 80% power and 5% 2-tailed significance level, 251 subjects were needed per treatment arm. To adjust for an estimated 20% discontinuations for reasons other than relapse, 628 subjects in total were needed. Actual relapse rates were 17% (risperidone LAI) and 31% (quetiapine).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "threshold for significance: 0.05 (2-sided)", "statisticalMethod": "Log Rank"}]}, {"type": "SECONDARY", "title": "Mean Relapse Free Period (Exploratory/Aripiprazole)", "description": "As for risperidone and quetiapine, relapse was defined as meeting any of the predefined criteria (adapted from Csernansky et al., 2002) on 2 consecutive evaluations during treatment, 3 to 5 days apart. Since aripiprazole was new on the market at the time the study was conducted, this aripiprazole analysis was exploratory.", "populationDescription": "Efficacy analysis set, defined as all subjects who received at least 1 dose of study medication and who had at least 1 efficacy assessment after baseline. This excluded 1 subject of the aripiprazole arm.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "days", "timeFrame": "Assessed at each visit from the moment the subject was randomized to a treatment arm (baseline visit) until the end of treatment (Week 104 or earlier)", "groups": [{"id": "OG000", "title": "Aripiprazole", "description": "oral, recommended maintenance dose of 10-30 mg q.d."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "44"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "314", "spread": "20.4"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline to Endpoint in Total Positive and Negative Syndrome Scale (PANSS) Score", "description": "The neuropsychiatric symptoms of schizophrenia were assessed by means of the 30-item PANSS scale. The PANSS scale provides a total score (sum of the scores of all 30 items) and scores for 3 subscales, i.e., the positive subscale (7 items), the negative subscale (7 items), and the general psychopathology subscale (16 items).\n\nEach item of the scale is to be scored on a scale of 1 (absent) to 7 (extreme).", "populationDescription": "Efficacy analysis set, defined as all subjects who received at least 1 dose of study medication and had at least 1 efficacy assessment after baseline. This excluded 2 subjects of the risperidone LAI, 11 of the quetipaine, and 1 of the aripiprazole arm. One additional subject in each the risperidone LAI and quetiapine arm did not have PANSS data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Assessed at each visit from the moment the subject was randomized to a treatment arm (baseline visit) until the end of treatment (Week 104 or earlier)", "groups": [{"id": "OG000", "title": "Risperidone LAI", "description": "Risperidone Long Acting Injectable (LAI) intramuscular injection, dose of 25, 37.5, or 50 mg every 2 weeks"}, {"id": "OG001", "title": "Quetiapine", "description": "oral Quetiapine, target dose of 300-400 mg twice daily (b.i.d.) or three times daily (t.i.d.)"}, {"id": "OG002", "title": "Aripiprazole", "description": "oral Aripiprazole, recommended maintenance dose of 10-30 mg once daily (q.d.)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "326"}, {"groupId": "OG001", "value": "325"}, {"groupId": "OG002", "value": "44"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.3", "spread": "25.65"}, {"groupId": "OG001", "value": "-1.1", "spread": "26.28"}, {"groupId": "OG002", "value": "-7.7", "spread": "27.99"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Between-group comparison of the change from baseline to endpoint in total PANSS score. The endpoint of the study was based on the Last Observation Carried Forward (LOCF) principle, i.e., it was defined as the last available visit during the study with non-missing data for a parameter (excluding the baseline value).", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Within-group comparison of the change from baseline to endpoint in total PANSS score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon signed-rank test", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG001"], "groupDescription": "Within-group comparison of the change from baseline to endpoint in total PANSS score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1026", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon signed-rank test", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Endpoint in Clinical Global Impression Scale (CGI) Score", "description": "The 7-point CGI scale of Severity (CGI-S) was used to assess the severity of a subject's psychotic condition (0= normal, not at all ill, 1= borderline, etc. and 6= among the most extremely ill subjects).", "populationDescription": "Efficacy analysis set, defined as all subjects who received at least 1 dose of study medication and had at least 1 efficacy assessment after baseline. This excluded 2 subjects of the risperidone LAI arm, 11 of the quetipaine arm, and 1 of the aripiprazole arm. One additional subject in the risperidone LAI arm did not have CGI data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Assessed at each visit from the moment the subject was randomized to a treatment arm (baseline visit) until the end of treatment (Month 24 or earlier)", "groups": [{"id": "OG000", "title": "Risperidone LAI", "description": "Risperidone Long Acting Injectable (LAI) intramuscular injection, dose of 25, 37.5, or 50 mg every 2 weeks"}, {"id": "OG001", "title": "Quetiapine", "description": "oral Quetiapine, target dose of 300-400 mg twice daily (b.i.d.) or three times daily (t.i.d.)"}, {"id": "OG002", "title": "Aripiprazole", "description": "oral Aripiprazole, recommended maintenance dose of 10-30 mg once daily (q.d.)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "326"}, {"groupId": "OG001", "value": "326"}, {"groupId": "OG002", "value": "44"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-0.3", "spread": "1.25"}, {"groupId": "OG001", "value": "0.1", "spread": "1.24"}, {"groupId": "OG002", "value": "-0.1", "spread": "1.32"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Between-group comparison of the change from baseline to endpoint in CGI-S score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Within-group comparison of the change from baseline to endpoint in CGI-S score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon signed-rank test", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG001"], "groupDescription": "Within-group comparison of the change from baseline to endpoint in CGI-S score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0446", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon signed-rank test", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}]}, {"type": "SECONDARY", "title": "Change From Baseline to Endpoint in Short-Form Health Survey 12 (SF-12) Scores", "description": "Quality of life was assessed by means of the 12-item SF-12\u00ae survey. Two parameters, i.e., PCS (physical component summary) and MCS (mental component summary) were calculated. Both components scores range from 0 to 100 with higher scores indicating better QOL.", "populationDescription": "Efficacy analysis set, defined as all subjects who received at least 1 dose of study medication and had at least 1 efficacy assessment after baseline. This excluded 2 subjects of the risperidone LAI, 11 of the quetipaine, and 1 of the aripiprazole arm. An additional 32, 32, and 2 subjects in the respective arms did not have SF-12 data.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "units on a scale", "timeFrame": "Assessed at the moment the subject was randomized to a treatment arm (baseline visit) and after 1, 3, 6, 12, 18, and 24 months of treatment", "groups": [{"id": "OG000", "title": "Risperidone LAI", "description": "Risperidone Long Acting Injectable (LAI) intramuscular injection, dose of 25, 37.5, or 50 mg every 2 weeks"}, {"id": "OG001", "title": "Quetiapine", "description": "oral Quetiapine, target dose of 300-400 mg twice daily (b.i.d.) or three times daily (t.i.d.)"}, {"id": "OG002", "title": "Aripiprazole", "description": "oral Aripiprazole, recommended maintenance dose of 10-30 mg once daily (q.d.)"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "295"}, {"groupId": "OG001", "value": "294"}, {"groupId": "OG002", "value": "42"}]}], "classes": [{"title": "PCS score", "categories": [{"measurements": [{"groupId": "OG000", "value": "2.1", "spread": "9.04"}, {"groupId": "OG001", "value": "1.0", "spread": "9.31"}, {"groupId": "OG002", "value": "2.4", "spread": "10.36"}]}]}, {"title": "MCS score", "categories": [{"measurements": [{"groupId": "OG000", "value": "3.2", "spread": "10.43"}, {"groupId": "OG001", "value": "2.7", "spread": "10.88"}, {"groupId": "OG002", "value": "4.9", "spread": "12.10"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "groupDescription": "Between-group comparison of the change from baseline to endpoint in PCS score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.0941", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Within-group comparison of the change from baseline to endpoint in PCS score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon signed-rank test", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG001"], "groupDescription": "Within-group comparison of the change from baseline to endpoint in PCS score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.1146", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon signed-rank test", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000", "OG001"], "groupDescription": "Between-group comparison of the change from baseline to endpoint in MCS score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "0.5589", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon (Mann-Whitney)", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG000"], "groupDescription": "Within-group comparison of the change from baseline to endpoint in MCS score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon signed-rank test", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}, {"groupIds": ["OG001"], "groupDescription": "Within-group comparison of the change from baseline to endpoint in MCS score. The endpoint of the study was based on the LOCF principle.", "testedNonInferiority": false, "nonInferiorityType": "SUPERIORITY_OR_OTHER", "pValue": "<0.0001", "pValueComment": "The statistical test was interpreted at the 5% significance level.", "statisticalMethod": "Wilcoxon signed-rank test", "ciPctValue": "95", "ciNumSides": "TWO_SIDED"}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "timeFrame": "All Adverse Events (AEs) occurring between the first study-related procedure, i.e. screening visit, and 6 weeks after the last injection of risperidone LAI or the last intake of quetiapine or aripiprazole (24 months after baseline) were reported.", "description": "AEs described hereafter are treatment-emergent AEs, defined as AEs that were new in onset or aggravated in severity following treatment start.", "eventGroups": [{"id": "EG000", "title": "Risperidone LAI", "description": "Risperidone Long Acting Injectable (LAI) intramuscular injection, dose of 25, 37.5, or 50 mg every 2 weeks", "seriousNumAffected": 63, "seriousNumAtRisk": 329, "otherNumAffected": 201, "otherNumAtRisk": 329}, {"id": "EG001", "title": "Quetiapine", "description": "oral Quetiapine, target dose of 300-400 mg twice daily (b.i.d.) or three times daily (t.i.d.)", "seriousNumAffected": 77, "seriousNumAtRisk": 337, "otherNumAffected": 213, "otherNumAtRisk": 337}, {"id": "EG002", "title": "Aripiprazole", "description": "oral Aripiprazole, recommended maintenance dose of 10-30 mg once daily (q.d.)", "seriousNumAffected": 7, "seriousNumAtRisk": 45, "otherNumAffected": 28, "otherNumAtRisk": 45}], "seriousEvents": [{"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Abnormal behavior", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Acquired methaemoglobinaemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Acute myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 45}]}, {"term": "Acute psychosis", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Affect lability", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Aggression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 3, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Agitation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Akathisia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Alcohol poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Alcoholism", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Anal abscess", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Anal fistula", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Ankle fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Asthma", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 45}]}, {"term": "Brain contusion", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Bronchitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Cerebrovascular accident", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Chronic obstructive airways disease", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Coma", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Completed suicide", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Condition aggravated", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Constipation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Cyst", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Cyst removal", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Deep vein thrombosis", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Delirium", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 45}]}, {"term": "Delusion", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 45}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Depression suicidal", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Diabetes mellitus", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Disturbance in social behavior", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Drug level decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Drug toxicity", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Epilepsy", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Fall", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Family stress", "organSystem": "Social circumstances", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Gastic ulcer", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Hallucination", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Head injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Hypothyroidism", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Inguinal hernia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 3, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Irritability", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Ischaemic stroke", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Joint dislocation", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Lung injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Major depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Mental disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Multiple fractures", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Myocardial infarction", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Ovarian cancer", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Ovarian cyst", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Panic disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Parkinsonism", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Peptic ulcer perforation", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Pneumonia", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Poisoning", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Psychotic disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 45}]}, {"term": "Refractory anemia", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Renal failure acute", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Respiratory failure", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Restlessness", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Schizoaffective disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Schizophrenia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Schizophrenia, disorganized type", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Schizophrenia, paranoid type", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Self injurious behavior", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Sleep disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Social problem", "organSystem": "Social circumstances", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Status epilepticus", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 45}]}, {"term": "Suicidal ideation", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Suicide attempt", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 5, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Surgery", "organSystem": "Surgical and medical procedures", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Suspiciousness", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Tibia fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Uterine leiomyoma", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Wrist fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}], "otherEvents": [{"term": "Anxiety", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 39, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 30, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 7, "numAtRisk": 45}]}, {"term": "Asthenia", "organSystem": "General disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 45}]}, {"term": "Delusion", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 4, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 45}]}, {"term": "Depression", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 15, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 45}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 15, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 4, "numAtRisk": 45}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 16, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 45}]}, {"term": "Hyperprolactinaemia", "organSystem": "Endocrine disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 43, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 5, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Insomnia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 36, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 11, "numAtRisk": 45}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 5, "numAtRisk": 45}]}, {"term": "Schizophrenia", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 4, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Sleep disorder", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 8, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 2, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 45}]}, {"term": "Somnolence", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 38, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 45}]}, {"term": "Tension", "organSystem": "Psychiatric disorders", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 14, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 45}]}, {"term": "Weight decreased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 6, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 3, "numAtRisk": 45}]}, {"term": "Weight increased", "organSystem": "Investigations", "sourceVocabulary": "MedDRA (8.0)", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 23, "numAtRisk": 329}, {"groupId": "EG001", "numAffected": 20, "numAtRisk": 337}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 45}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "GT60", "restrictiveAgreement": true}, "pointOfContact": {"title": "EMEA Medical Affairs Director Psychiatry", "organization": "Janssen Cilag European Medical Affairs", "phone": "+34 91 7228043"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-26", "removedCountries": ["Italy"]}, "conditionBrowseModule": {"meshes": [{"id": "D000012008", "term": "Recurrence"}, {"id": "D000012559", "term": "Schizophrenia"}, {"id": "D000011618", "term": "Psychotic Disorders"}], "ancestors": [{"id": "D000019967", "term": "Schizophrenia Spectrum and Other Psychotic Disorders"}, {"id": "D000001523", "term": "Mental Disorders"}, {"id": "D000020969", "term": "Disease Attributes"}, {"id": "D000010335", "term": "Pathologic Processes"}], "browseLeaves": [{"id": "M4815", "name": "Mental Disorders", "relevance": "LOW"}, {"id": "M15376", "name": "Schizophrenia", "asFound": "Schizophrenia", "relevance": "HIGH"}, {"id": "M14473", "name": "Psychotic Disorders", "asFound": "Psychotic Disorders", "relevance": "HIGH"}, {"id": "M14850", "name": "Recurrence", "asFound": "Relapse", "relevance": "HIGH"}, {"id": "M21838", "name": "Schizophrenia Spectrum and Other Psychotic Disorders", "relevance": "LOW"}, {"id": "M22700", "name": "Disease Attributes", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BXM", "name": "Behaviors and Mental Disorders"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000018967", "term": "Risperidone"}, {"id": "D000068180", "term": "Aripiprazole"}, {"id": "D000069348", "term": "Quetiapine Fumarate"}], "ancestors": [{"id": "D000012702", "term": "Serotonin Antagonists"}, {"id": "D000018490", "term": "Serotonin Agents"}, {"id": "D000018377", "term": "Neurotransmitter Agents"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000014150", "term": "Antipsychotic Agents"}, {"id": "D000014149", "term": "Tranquilizing Agents"}, {"id": "D000002492", "term": "Central Nervous System Depressants"}, {"id": "D000011619", "term": "Psychotropic Drugs"}, {"id": "D000018492", "term": "Dopamine Antagonists"}, {"id": "D000015259", "term": "Dopamine Agents"}, {"id": "D000000928", "term": "Antidepressive Agents"}, {"id": "D000018491", "term": "Dopamine Agonists"}, {"id": "D000058825", "term": "Serotonin 5-HT1 Receptor Agonists"}, {"id": "D000017366", "term": "Serotonin Receptor Agonists"}, {"id": "D000058830", "term": "Serotonin 5-HT2 Receptor Antagonists"}, {"id": "D000065127", "term": "Dopamine D2 Receptor Antagonists"}], "browseLeaves": [{"id": "M16904", "name": "Antipsychotic Agents", "relevance": "LOW"}, {"id": "M229", "name": "Aripiprazole", "asFound": "Association", "relevance": "HIGH"}, {"id": "M20999", "name": "Risperidone", "asFound": "Stable", "relevance": "HIGH"}, {"id": "M399", "name": "Quetiapine Fumarate", "asFound": "Sexual", "relevance": "HIGH"}, {"id": "M15512", "name": "Serotonin", "relevance": "LOW"}, {"id": "M20504", "name": "Neurotransmitter Agents", "relevance": "LOW"}, {"id": "M14474", "name": "Psychotropic Drugs", "relevance": "LOW"}, {"id": "M7473", "name": "Dopamine", "relevance": "LOW"}, {"id": "M20596", "name": "Dopamine Antagonists", "relevance": "LOW"}, {"id": "M17962", "name": "Dopamine Agents", "relevance": "LOW"}, {"id": "M4247", "name": "Antidepressive Agents", "relevance": "LOW"}, {"id": "M20595", "name": "Dopamine Agonists", "relevance": "LOW"}, {"id": "M29240", "name": "Serotonin 5-HT1 Receptor Agonists", "relevance": "LOW"}, {"id": "M19648", "name": "Serotonin Receptor Agonists", "relevance": "LOW"}], "browseBranches": [{"abbrev": "CNSDep", "name": "Central Nervous System Depressants"}, {"abbrev": "PsychDr", "name": "Psychotropic Drugs"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "CaAg", "name": "Cardiotonic Agents"}]}}, "hasResults": true}